Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression

Diabetes mellitus (DM)-induced cardiac morbidities have been the leading cause of death among diabetic patients. Recently, sodium-glucose cotransporter-2 (SGLT-2) inhibitors including empagliflozin (EMPA), which have been approved for the treatment of DM, have gained attention for their cardioprotec...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdulrahman, Nabeel, Ibrahim, Meram, Joseph, Jensa Mariam, Elkoubatry, Hanan Mahmoud, Al-Shamasi, Al-Anood, Rayan, Menatallah, Gadeau, Alain Pierre, Ahmed, Rashid, Eldassouki, Hussein, Hasan, Anwarul, Mraiche, Fatima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068664/
https://www.ncbi.nlm.nih.gov/pubmed/35334035
http://dx.doi.org/10.1007/s11010-022-04411-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068664/
https://www.ncbi.nlm.nih.gov/pubmed/35334035
http://dx.doi.org/10.1007/s11010-022-04411-6

Ejemplares similares